{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:07:53Z","timestamp":1791259673496,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,6,30]],"date-time":"2015-06-30T00:00:00Z","timestamp":1435622400000},"content-version":"vor","delay-in-days":910,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.bbmt.2012.07.021","type":"journal-article","created":{"date-parts":[[2012,8,4]],"date-time":"2012-08-04T10:47:26Z","timestamp":1344077246000},"page":"75-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["High Alloreactivity of Low-Dose Prophylactic Donor Lymphocyte Infusion in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation with an Alemtuzumab-Containing Conditioning Regimen"],"prefix":"10.1016","volume":"19","author":[{"given":"Maria","family":"Liga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Triantafyllou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tiniakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polyxeni","family":"Lambropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Karakantza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C.","family":"Zoumbos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Spyridonidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2012.07.021_bib1","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"Schmid","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.07.021_bib2","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/leu.2011.351","volume":"26","author":"Spyridonidis","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2012.07.021_bib3","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/bmt.2008.259","article-title":"Donor lymphocyte infusions. The long and winding road: how should it be traveled?","volume":"42","author":"Tomblyn","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.07.021_bib4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/bmt.2008.212","article-title":"Mixed chimerism in SCT: conflict or peaceful coexistence?","volume":"42","author":"Liesveld","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.07.021_bib5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.bmt.1705707","article-title":"Chimerism does not predict for outcome after alemtuzumab-based conditioning (letter)","volume":"40","author":"Michaelis","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.07.021_bib6","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bmt.1705937","article-title":"Chimerism does not predict for outcome after alemtuzumab-based conditioning: lineage-specific analysis of chimerism of specific diseases may be more informative","volume":"41","author":"Lim","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.07.021_bib7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3109\/10428190903200790","article-title":"Patterns and kinetics of T-cell chimerism after allotransplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence","volume":"50","author":"van Besien","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2012.07.021_bib8","first-page":"801","article-title":"Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia","volume":"88","author":"Barrios","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2012.07.021_bib9","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/sj.leu.2403719","article-title":"Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation","volume":"19","author":"Zeiser","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2012.07.021_bib10","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1399-0012.2005.00347.x","article-title":"Capillary electrophoresis for chimerism monitoring by PCR amplification of microsatellite markers after allogeneic hematopoietic cell transplantation","volume":"19","author":"Spyridonidis","year":"2005","journal-title":"Clin Transplant"},{"key":"10.1016\/j.bbmt.2012.07.021_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1751-553X.2010.01249.x","article-title":"Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapse","volume":"33","author":"Horky","year":"2011","journal-title":"Int J\u00a0Lab Hematol"},{"key":"10.1016\/j.bbmt.2012.07.021_bib12","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1182\/blood-2011-04-348805","article-title":"Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation","volume":"118","author":"Rettinger","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.07.021_bib13","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2003-05-1513","article-title":"Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses","volume":"103","author":"Peggs","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.07.021_bib14","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1182\/blood-2002-02-0506","article-title":"The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation","volume":"100","author":"Marks","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.07.021_bib15","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1200\/JCO.2010.32.1711","article-title":"Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell\u2013depleted allogeneic transplantation for Hodgkin's lymphoma","volume":"29","author":"Peggs","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.07.021_bib16","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/bmt.2010.308","article-title":"Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia","volume":"46","author":"Spyridonidis","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.07.021_bib17","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group Study","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.07.021_bib18","first-page":"825","article-title":"1994 Consensus Conference\u00a0on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.07.021_bib19","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: Diagnosis and Staging Working Group Report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.07.021_bib20","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1365-2141.1995.tb08356.x","article-title":"T-cell\u2013depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse","volume":"89","author":"Naparstek","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2012.07.021_bib21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/sj.bmt.1701131","article-title":"T\u00a0cell\u2013depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect","volume":"21","author":"Barrett","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.07.021_bib22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/sj.bmt.1702726","article-title":"Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease","volume":"27","author":"de Lima","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.07.021_bib23","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/sj.leu.2402203","article-title":"Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions","volume":"15","author":"Schaap","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2012.07.021_bib24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/bbmt.2002.v8.abbmt080625","article-title":"Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion","volume":"8","author":"Soiffer","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.07.021_bib25","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","article-title":"Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"Schmid","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.07.021_bib26","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.bbmt.2006.08.034","article-title":"T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome","volume":"12","author":"Montero","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.07.021_bib27","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.bmt.1705981","article-title":"A\u00a0pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation","volume":"41","author":"Lutz","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.07.021_bib28","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.bmt.1703883","article-title":"Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions","volume":"31","author":"Raiola","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.07.021_bib29","first-page":"736","article-title":"An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation","volume":"116","author":"Huang","year":"2003","journal-title":"Chin Med J"},{"key":"10.1016\/j.bbmt.2012.07.021_bib30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2002.20.2.405","article-title":"Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation","volume":"20","author":"Levine","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.07.021_bib31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.bmt.1704328","article-title":"A\u00a0pilot study of cytoreductive chemotherapy combined with infusion of additional peripheral blood stem cells reserved at time of harvest for transplantation in case of relapsed hematologic malignancies after allogeneic peripheral blood stem cell transplant","volume":"33","author":"Kim","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.07.021_bib32","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/bmt.2011.45","article-title":"Induction of graft-versus-malignancy effect after unrelated allogeneic PBSCT using donor lymphocyte infusions derived from frozen aliquots of the original graft","volume":"47","author":"Hasskarl","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.07.021_bib33","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/bmt.2011.101","article-title":"CT60 single-nucleotide polymorphism as a surrogate marker for donor lymphocyte infusion outcome after allogeneic cell transplantation for acute leukemia","volume":"47","author":"Metaxas","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.07.021_bib34","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2003-07-2344","article-title":"Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning","volume":"103","author":"Bethge","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.07.021_bib35","first-page":"1559","article-title":"Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumab","volume":"91","author":"von dem Borne","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2012.07.021_bib36","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1100\/tsw.2011.16","article-title":"Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia","volume":"11","author":"Bacher","year":"2011","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.bbmt.2012.07.021_bib37","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1182\/blood-2006-05-023416","article-title":"Antitumor effects of HSV-TK\u2013engineered donor lymphocytes after allogeneic stem-cell transplantation","volume":"109","author":"Ciceri","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.07.021_bib38","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"di Stasi","year":"2011","journal-title":"N\u00a0Engl J Med"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879112003102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879112003102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:44:41Z","timestamp":1761057881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879112003102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S1083879112003102"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2012.07.021","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High Alloreactivity of Low-Dose Prophylactic Donor Lymphocyte Infusion in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation with an Alemtuzumab-Containing Conditioning Regimen","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2012.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}